L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Amoneta Diagnostics offers a blood diagnostic test to detect and follow the Alzheimer’s Disease pathology, which shall also be used as an optimizing method for present and future treatments and drug development projects.
Huningue, Grand-Est, France
Send a message
Scentific American publishes ADDF President's article on the need for New Biomarkers to diagnose early Alzheimer in blood.
The Scientific American published an article written by Dr. Howard Fillit, the Founding Executive Director and Chief Science Officer at the Alzheimer's Drug Discovery Foundation (ADDF), one of the most acknowledged Key Opinion Leaders in the field of Alzheimer's Disease.
The article points to the unmet need for blood biomarkers for an inexpensive and noninvasive clinical diagnosis of Alzheimer's Disease. According to Dr. Fillit, such a test would not only facilitate the diagnosis but also stimulate better treatments for the Alzheimer's Disease, for which (in sharp contrast to other illnesses and despite many efforts as well as huge expenses and hundreds of clinical trials), no new treatment have been approved in the past 16 years.
This article confirms, the real value of ADDIA, a blood diagnostic test based on a combination of 2 biomarkers. ADDIA is a multicentric proof-of-performance biomarker study, funded by the European Union Horizon-2020 Program.
Start in 2014
Amoneta Diagnostics SAS is founded by Firalis SA and SODIV.
ADDIA Project proposal has been awarded with a "Seal of Excellence" and a 5 Mio € grant by the EU.
Amoneta obtained approvals from various ethic committee for its ADDIA multicentric clinical study.
Amoneta launched its ADDIA multicentric study aiming to do the proof-of-performance of its test.
Strasbourg Hospital finalized recruitments for the Chronobiological study (part of ADDIA Program).
to be continued ...